Zevra Therapeutics Acquires Acer Therapeutics
November 20, 2023
Zevra Therapeutics completed the acquisition of Acer Therapeutics in a stock-and-contingent-value-rights transaction, bringing the FDA-approved product OLPRUVA and clinical-stage candidate EDSIVO into Zevra's portfolio and transitioning Zevra to a commercial-stage rare disease company. The deal included Zevra's purchase of Acer's senior secured debt and issuance of approximately 2.96 million shares plus CVRs (up to $76 million), and was followed by a registered direct offering to a healthcare-focused investment fund.
- Buyers
- Zevra Therapeutics, Inc.
- Targets
- Acer Therapeutics, Inc.
- Sellers
- Acer Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Aceragen Acquires Arrevus to Expand Late-Stage Rare Disease Pipeline
October 28, 2021
Biotechnology
Aceragen, Inc. acquired clinical-stage biopharmaceutical company Arrevus, Inc., adding Arrevus' lead oral anti-infective candidate ARV-1801 (renamed ACG-721) and several preclinical programs to Aceragen's rare-disease pipeline. The deal brings additional clinical and regulatory capabilities to Aceragen and is expected to be accretive as the company advances registrational and Phase 2/3 studies in cystic fibrosis and other orphan indications.
-
Idera Pharmaceuticals Acquires Aceragen
September 28, 2022
Biotechnology
Idera Pharmaceuticals completed an all-stock acquisition of Aceragen, a privately held biotech focused on rare pulmonary and rheumatic diseases, adding Aceragen's lead programs ACG-701 and ACG-801 to Idera's pipeline. The transaction was structured as a stock-for-stock exchange, includes management appointments from Aceragen, and is expected to provide pro forma cash runway into Q3 2023 while advancing Aceragen's clinical milestones.
-
AbbVie Acquires Cerevel Therapeutics
December 6, 2023
Biotechnology
AbbVie Inc. acquired Cerevel Therapeutics for $45.00 per share, valuing Cerevel at approximately $8.7 billion, to bolster AbbVie's neuroscience pipeline. The deal adds Cerevel's clinical-stage assets—including emraclidine, tavapadon, CVL-354 and darigabat—and is intended to expand AbbVie's capabilities and commercial potential in psychiatric and neurological disorders.
-
Eli Lilly Acquires Verve Therapeutics
July 25, 2025
Biotechnology
Eli Lilly and Company completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage developer of one-time gene-editing therapies for cardiovascular disease. Lilly said the deal will integrate Verve's genetic-medicine programs into its cardiometabolic research to advance potential lifelong cardiovascular risk–reduction treatments.
-
Sorrento Therapeutics Acquires ACEA Therapeutics
June 1, 2021
Biotechnology
Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.
-
Advarra Acquires YourEncore
January 7, 2021
Healthcare Services
Advarra has acquired YourEncore, a provider of drug development and commercialization advisory and consulting services. The acquisition expands Advarra's consulting capabilities—combining YourEncore's centers of excellence in quality, regulatory, and clinical with Advarra's IRB, IBC review and clinical site technology offerings to better serve biopharmaceutical sponsors, device manufacturers and academic medical centers.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.